Single nucleotide polymorphisms within interferon signaling pathway genes are associated with colorectal cancer susceptibility and survival by Lu, S. et al.
Single Nucleotide Polymorphisms within Interferon
Signaling Pathway Genes Are Associated with Colorectal
Cancer Susceptibility and Survival
Shun Lu1¤, Barbara Pardini2, Bowang Cheng1, Alessio Naccarati2,3, Stefanie Huhn1,
Veronika Vymetalkova3,4, Ludmila Vodickova3,4,5, Thomas Buchler6, Kari Hemminki1,7, Pavel Vodicka3,4,
Asta Försti1,7*
1 Division of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany, 2 Human Genetics Foundation (HuGeF), Turin, Italy,
3 Department of Molecular Biology of Cancer, Institute of Experimental Medicine, Academy of Sciences of the Czech Republic, Prague, Czech Republic, 4 Institute of
Biology and Medical Genetics, 1st Medical Faculty, Charles University, Prague, Czech Republic, 5 Biomedical Centre, Faculty of Medicine in Pilsen, Charles University in
Prague, Pilsen, Czech Republic, 6 Department of Oncology, Thomayer Hospital, Prague, Czech Republic, 7 Center of Primary Health Care Research, Clinical Research
Center, Lund University, Malmö, Sweden
Abstract
Interferon (IFN) signaling has been suggested to play an important role in colorectal carcinogenesis. Our study aimed to
examine potentially functional genetic variants in interferon regulatory factor 3 (IRF3), IRF5, IRF7, type I and type II IFN and
their receptor genes with respect to colorectal cancer (CRC) risk and clinical outcome. Altogether 74 single nucleotide
polymorphisms (SNPs) were covered by the 34 SNPs genotyped in a hospital-based case-control study of 1327 CRC cases
and 758 healthy controls from the Czech Republic. We also analyzed these SNPs in relation to overall survival and event-free
survival in a subgroup of 483 patients. Seven SNPs in IFNA1, IFNA13, IFNA21, IFNK, IFNAR1 and IFNGR1 were associated with
CRC risk. After multiple testing correction, the associations with the SNPs rs2856968 (IFNAR1) and rs2234711 (IFNGR1)
remained formally significant (P = 0.0015 and P,0.0001, respectively). Multivariable survival analyses showed that the SNP
rs6475526 (IFNA7/IFNA14) was associated with overall survival of the patients (P = 0.041 and event-free survival among
patients without distant metastasis at the time of diagnosis, P = 0.034). The hazard ratios (HRs) for rs6475526 remained
statistically significant even after adjustment for age, gender, grade and stage (P = 0.029 and P = 0.036, respectively),
suggesting that rs6475526 is an independent prognostic marker for CRC. Our data suggest that genetic variation in the IFN
signaling pathway genes may play a role in the etiology and survival of CRC and further studies are warranted.
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Introduction
Colorectal cancer (CRC) is an important contributor to cancer
incidence and death, with more than 1.3 million new cases
resulting in about 694,000 deaths in 2012 worldwide (http://
globocan.iarc.fr/Default.aspx). Nutrition, lifestyle factors and
environment [1], as well as genetic events have been implicated
both in the causation of CRC and survival of patients after
diagnosis of CRC [2,3]. So far, 50 single nucleotide polymor-
phisms (SNPs) located in 40 loci have been associated with the risk
of CRC by genome-wide association studies (GWASs, http://
www.genome.gov/gwastudies/, [4–6]). Although molecular mark-
ers have been suggested for follow-up of treated CRC patients,
their complete clinical application is under evaluation. Clinico-
pathologic stage is still the main prognostic marker used in the
clinical practice.
Inflammatory responses play a crucial role in colorectal
carcinogenesis. Several studies, although not any GWAS, have
reported SNPs in immune-related genes to be associated with
CRC risk or prognosis [7–10]. Interferons (IFNs) are immune-
related proteins produced and released by host cells in response to
the presence of pathogens. IFN-mediated signaling has a diverse
range of functions, including antiviral and antimicrobial response,
antiproliferation, immunomodulation and apoptosis [11,12].
There are two main classes of IFNs, type I and type II. The two
type I IFNs, IFNA and IFNB, have been reported to have an effect
on tumor suppression and antiviral immune defense through
induction of p53 responses [13]. IFNG, the only type II IFN, has
been suggested to play a vital role in the disruption of the intestinal
epithelial barrier function [14,15]. It has also been identified as an
important modulator of immune-related genes, such as toll-like
receptor 3 (TLR3), the gene which showed association with CRC
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survival in our previous study [8]. Interferon regulatory factors
(IRFs) regulate IFNs and some IFN-inducible oncogenes by
serving as transcription mediators of pathogens and IFN-induced
signaling pathways. Interferon receptors are essential for IFNs to
exert their biological effects [11,12]. All type I IFNs bind to a
receptor composed of two subunits, IFNAR1 and IFNAR2, while
the type II interferon IFNG binds to another dimeric receptor
composed of IFNGR1 and IFNGR2.
So far, few studies have investigated the association between
genetic variants in the IFN signaling pathway and CRC. A
previous study examined genetic variation in IFNG, IFNGR1,
IFNGR2 and IRF1-9 with the risk and survival of colon and rectal
cancer [16]. In that study, tagSNP approach was applied; several
SNPs in IRFs, IFNG and its receptors were found to be associated
with CRC risk or survival [16]. To further explore the role of
genetic variants in the IFN signaling pathway genes in CRC, we
genotyped a set of potentially functional SNPs in the IRF3, IRF5,
IRF7, IFNA, IFNB, IFNE, IFNK, IFNW, IFNG, IFNAR1,
IFNAR2, IFNGR1 and IFNGR2 genes in a case-control study of
1327 CRC patients and 758 healthy controls from the Czech




All participants gave a written informed consent to the use of
their samples for research purpose. The study was approved by the
ethical committees of the participating institutes, the Institute of
Experimental Medicine, Academy of Sciences of the Czech
Republic, Prague, Czech Republic and the Institute for Clinical
and Experimental Medicine and Faculty Thomayer Hospital,
Prague, Czech Republic.
Study population
The case group contained 1327 CRC patients recruited
between the years 2004 and 2010 by several oncological
departments in the Czech Republic [17]. Their mean age (6
standard deviation) was 62.1 (610.7) years, and 61.7% of them
were men. The patients showed positive colonoscopic results for
malignancy, histologically confirmed as colon or rectal carcino-
mas. Patients who met the Amsterdam criteria I or II for
hereditary nonpolyposis colorectal cancer were not included in the
study [18]. General information about gender and age at diagnosis
was available for all patients. For 483 consecutively recruited,
incident cases diagnosed between 2003 and 2010, clinical data at
the time of diagnosis, including location of the tumor (colon/
rectum), International Union against Cancer (UICC) TNM stage
classification [size or direct extent of the primary tumor (T), degree
of spread to regional lymph nodes (N), presence of metastasis (M)]
and grade were available (Table 1). Information about distant
metastasis, relapse and date of death was also collected, with a
follow-up until August 31, 2011.
The control group contained 758 healthy individuals recruited
by a blood-donor center in one hospital in Prague [19]. These
disease-free individuals represent the general population of the
Czech Republic, which has a genetically quite uniform population
[20–22]. Their mean age (6 standard deviation) was 45.6 (68.3)
years, and 56.2% of them were men.
SNP selection
20 candidate genes were selected from IFN signaling pathway
based on their suggested functional role in CRC causation and
survival, including IFNA (1, 2, 4, 5, 7, 8, 13, 16, 17, and 21),
IFNB1, IFNK, IFNW1, IRF3, IRF5, IRF7, IFNAR1, IFNAR2,
IFNGR1, and IFNGR2 [8,13–15,23–28]. A total of 34 SNPs,
which captured 74 potentially functional SNPs, were selected for
genotyping in these genes from the International HapMap Project
(http://hapmap.ncbi.nlm.nih.gov) and the NCBI database
(http://www.ncbi.nlm.nih.gov) (Table 2) based on the following
criteria: minor allele frequency (MAF) $10% in Europeans;
location within the coding region (non-synonymous SNPs), the 59
and 39 untranslated regions (UTRs) and the promoter (up to
approximately 1 kb from the transcription start site); pairwise
linkage disequilibrium (LD, r2#0.80) between the SNPs in Utah
residents with Northern and Western European ancestry from the
CEPH collection (CEU). SNPnexus (http://snp-nexus.org/) was
used to predict functional consequences of the selected SNPs. For
the SNPs rs2856968, rs2243711 and rs6475526 (including SNPs
captured by these SNPs), which associated with CRC risk or
survival, we also used additional web-based tools [HaploReg v2
(http://www.broadinstitute.org) and SNPinfo Web Server (http://
snpinfo.niehs.nih.gov/cgi-bin/snpinfo/snpfunc.cgi)] to predict
their effects on potential regulatory elements.
Genotyping
In this project, whole genome amplified (WGA) DNA from
peripheral blood leukocytes was used [29,30]. The genotyping was
performed blinded by the case–control status of each sample. The
KASP allelic discrimination method (LGCgenomics, Middelsex,
UK) was used to genotype the selected SNPs. DNA amplification
was performed according to the LGCgenomics’ PCR conditions.
Genotype detection was performed using an ABI PRISM 7900HT
Sequence Detection system with SDS2.4 software (Applied
Biosystems). The sample set contained 138 duplicated samples as
quality controls. The genotype correlation between the duplicate
samples was.99%. Genotype call rate ranged between 97.0 and
99.5%.
Statistical analysis
The observed genotype frequencies in the controls were tested
for Hardy–Weinberg equilibrium (HWE) using the chi-square test.
Odds ratios (ORs) and 95% confidence intervals (CIs) for
associations between genotypes and CRC risk were calculated
by logistic regression (PROC LOGISTIC, SAS Version 9.2; SAS
Institute, Cary, NC), and adjusted for age and gender. To account
for multiple testing, the SNP Spectral Deposition (SNPSpD)
method for multilocus analyses was applied [24,31]_ENREF_31.
For a polymorphism with a variant allele frequency between 10
and 50%, the study had greater than 90% power to detect an OR
of 1.50 at a significance level of 0.05 (PS—software for power and
sample size calculation, http://biostat.mc.vanderbilt.edu/twiki/
bin/view/Main/PowerSampleSize). In this study, we analyzed
overall survival in the group of 483 consecutively recruited,
incident CRC cases diagnosed between 2003 and 2010, using the
date of death or end of the study (August 31, 2011) as the end
point of follow-up. Median follow-up time for the 483 patients was
58 months. For event-free survival in patients with non-metastatic
disease at the time of diagnosis (n = 325), date of distant metastasis,
relapse, death or end of the study was used as the end point of
follow-up. Event-free survival was defined as the time from surgery
to the occurrence of distant metastasis, recurrence or death,
whichever came first. Median follow-up time was 55 months. The
survival curves for overall and event-free survival were derived by
the Kaplan–Meier method (PROC LIFETEST, SAS Version 9.2)
and compared using log-rank test. The relative risk of death was
estimated as hazard ratio (HR) using Cox regression (PROC
PHREG, SAS Version 9.2). Multivariable survival analyses were
Lu_IFNs in Colorectal Cancer
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adjusted for age, gender, T, N, M, TNM stage and grade
separately, and in a final model for age, gender, tumor location,
TNM stage and grade. Covariables were stratified for in the
analysis if they did not meet the proportional hazards assumption.
Results
Altogether, 74 SNPs with MAF $10% in the CEU population
were located within the regions of interest (promoter, 59 and
39UTR, non-synonymous SNPs) of the 20 genes IFNA (1, 2, 4, 5,
7, 8, 13, 16, 17, and 21), IFNB1, IFNK, IFNW1, IRF3, IRF5,
IRF7, IFNAR1, IFNAR2, IFNGR1 and IFNGR2. From these,
34 SNPs were selected for genotyping based on LD (r2#0.80)
(Table 2). All IFNA genes as well as the IFNB1, IFNK and
IFNW1 genes are located at the same locus at 9p21.3. Thus,
although the SNPs were selected based on their potential
functional effect on a specific gene, they may capture, and thus
give information, about additional SNPs and other genes at the
same locus, as shown in Table 2 and Figure S1. The genotype
distribution of all 34 genotyped polymorphisms was consistent
with HWE in the control group (P.0.05). The MAFs in the
control population were similar to the ones reported by the
HapMap project for the CEU population (Table 2).
Table 1. Characteristics of the 483 newly diagnosed Czech colorectal cancer patients.
Characteristics No. (%)










1, 2 309 (63.98)
3, 4 105 (21.74)
Missing 69 (14.29)
T
T1, T2 88 (18.22)











Stage I 55 (11.39)
Stage II 128 (26.50)
Stage III 123 (25.47)








No., number of patients; T, size or direct extent of the primary tumor; N, degree of spread to regional lymph nodes; M, presence of metastasis.
doi:10.1371/journal.pone.0111061.t001
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Seven SNPs were associated with CRC susceptibility
Minor allele carriers of the IFNA13 promoter SNP rs641734, and
IFNA21 39UTR SNP rs2939, had a decreased risk of CRC, while
the minor allele carriers of the IFNA1 missense SNP rs33965070,
IFNK 39UTR SNP rs700782, IFNAR1 39UTR SNP rs2834202,
IFNAR1 SNP rs2856968, which was genotyped instead of the
promoter SNPs in the same gene, and IFNGR1 59UTR SNP
rs2234711 had an increased risk of CRC (Table 3). These
associations did not differ by tumor location at colon or rectum
(data not shown). To correct for multiple testing, we used the
SNPSpD approach. The study-wise effective number of independent
markers Meff was calculated to be 27, which gave the significance
threshold of 0.0019. Thus, the associations with the SNPs rs2856968
(IFNAR1) and rs2234711 (IFNGR1) remained formally significant
(P = 0.0015 and P,0.0001, respectively). The other genotyped
SNPs were not associated with CRC risk (Table S1).
Two SNPs were associated with CRC survival
In the univariable analysis, the following parameters were
associated with overall survival rate: gender, size or direct extent of
the primary tumor (T), degree of spread to regional lymph nodes
(N), presence of metastasis (M), TNM stage and tumor grade
(Table S2). Interestingly, the SNP rs6475526, located about 2.2 kb
59 of IFNA14 and genotyped instead of the IFNA7 promoter
SNPs, and the IFNA21 promoter SNP rs7047687, showed an
association with overall survival among the 483 patients with
follow-up data (HR 1.33, 95%CI 1.01–1.74 and HR 0.77, 95%CI
0.59–0.99, respectively) (Table 4, Table S3) and SNP rs6475526
also with event-free survival among patients without distant
metastasis at the time of diagnosis (HR 1.51, 95%CI 1.03–2.21)
(Table 4). Moreover, compared to the GG genotype carries, the
AA carries of IRF5 SNP rs11770859 had a better overall survival
(HR 0.67, 95%CI 0.47–0.96). The Kaplan-Meier survival curves
representing the overall and event-free survival rates of the
patients according to their rs6475526 genotypes and the overall
survival rates of the patients according to their rs7047687
genotypes are presented in Figure 1. The survival differences
between the carriers of the different genotypes were statistically
significant with log-rank p-values of 0.04, 0.03 and 0.04,
respectively. The associations were strongest among stage 1
Table 3. Associations between candidate SNPs and colorectal cancer susceptibility.
Gene SNP rs# Genotype Case No. (%)1 Control No. (%)1 OR (95% CI) P value2
IFNA1 rs33965070 CC 1060 (82.23) 640(86.37) 1
CG 229 (17.77) 101 (13.63) 1.37 (1.06–1.75) 0.015
GG 0 0
CG+GG 229 (17.77) 101 (13.63) 1.37 (1.06–1.75) 0.015
IFNA13 rs641734 CC 900 (69.39) 473 (64.35) 1
CT 358 (27.60) 239 (32.52) 0.79 (0.65–0.96) 0.018
TT 39 (3.01) 23 (3.13) 0.89 (0.53–1.52) 0.668
TC+CC 397 (30.61) 262 (35.65) 0.80 (0.66–0.97) 0.024
IFNA21 rs2939 TT 882 (67.90) 466 (62.38) 1
CT 383 (29.48) 257 (34.40) 0.79 (0.65–0.95) 0.016
CC 34 (2.62) 24 (3.21) 0.75 (0.44–1.28) 0.288
CT+CC 417 (32.10) 281 (37.62) 0.79 (0.65–0.95) 0.012
IFNK rs700782 GG 743 (57.15) 467 (62.18) 1
AG 484 (37.23) 252 (33.56) 1.20 (1.00–1.47) 0.054
AA 73 (5.62) 32 (4.26) 1.43 (0.93–2.22) 0.102
AG+AA 557 (42.85) 284 (37.82) 1.23 (1.03–1.49) 0.023
IFNAR1 rs2834202 AA 715 (56.08) 448 (62.22) 1
AG 481 (37.73) 230 (31.94) 1.32 (1.08–1.59) 0.007
GG 79 (6.20) 42 (5.83) 1.18 (0.79–1.75) 0.412
AG+GG 560 (43.92) 272 (37.78) 1.30 (1.08–1.56) 0.007
IFNAR1 rs2856968 AA 469 (37.05) 321 (44.15) 1
AG 583 (46.05) 311 (42.78) 1.28 (1.05–1.56) 0.014
GG 214 (16.90) 95 (13.07) 1.54 (1.16–2.04) 0.003
AG+GG 797 (62.95) 406 (55.85) 1.35 (1.12–1.61) 0.0015
IFNGR1 rs2234711 TT 395 (30.91) 266 (40.00) 1
CT 673 (52.66) 299 (44–96) 1.52 (1.23–1.85) ,0.0001
CC 210 (16.43) 100 (15.04) 1.41 (1.06–1.89) 0.017
CT+CC 883 (69.09) 399 (60.00) 1.49 (1.22–1.82) ,0.0001
1Number of cases may differ due to missing data.
2Two-sided X2 test for genotype distribution between the cases and controls, adjusted for age and gender.
No., number of subjects; OR, odds ratio; CI, confidence interval. Bold numbers indicate a statistical significance at 5% level.
Bold numbers in Italics indicate a statistical significance at 5% level after adjustment for multiple comparisons.
doi:10.1371/journal.pone.0111061.t003
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patients: the HR for overall survival was 4.04 (95%CI 1.13–14.53)
for SNP rs6475526 and 0.29 (95%CI 0.10–0.83) for IFNA21 SNP
rs7047687; the HR for event-free survival was 3.78 (95%CI 1.27–
11.67) for SNP rs6475526 (Table S4). However, these results
should be taken with caution due to small number of patients who
died (11/29 and 6/34 variant allele carriers of the stage 1 patients,
respectively), and because the HRs among stage 2, 3 and 4 patients
were similar to the ones for all 483 patients (Table S4). Moreover,
no differences in overall survival between patients with grade 1+2
and grade 3+4 tumors or between patients without (M0) and with
distant metastasis (M1) were observed. Stratified analysis accord-
ing to tumor location showed that the worse overall survival of
SNP rs6475526 was restricted to patients with rectal cancer (HR
2.10, 95%CI 1.31–3.36; colon cancer HR 1.01, 95%CI 0.72–
1.42), the same tendency was observed also for event-free survival
(rectal cancer HR 1.90, 95%CI 1.06–3.40; colon cancer HR 1.27,
95%CI 0.77–2.10) (Table S4).
In the multivariable analysis, the HRs for rs6475526 remained
statistically significant after adjustment for age, gender, tumor
location and TNM stage (overall survival HR 1.38, 95% CI 1.04–
1.84; event-free survival HR 1.55, 95% CI 1.03–2.32) (Table 4).
Discussion
IFN-signaling system may play a critical role in carcinogenesis
of CRC by regulating immune responses during inflammation and
it may additionally affect survival of CRC patients [8,13–
16,20,25]. In this genetic association study, we investigated the
associations between 34 SNPs capturing 74 potentially functional
SNPs in the IFN-signaling system genes and CRC risk and clinical
outcome. Two SNPs located in the IFNAR1 and IFNGR1 genes
exhibited an association with CRC risk. In the multivariable
survival analysis, the SNP rs6475526, located about 2.2 kb of
IFNA14 and capturing two promoter SNPs in IFNA7, was
associated with overall survival and also with event-free survival of
non-metastatic CRC patients. These SNPs together with other
common variants identified by the GWASs and the candidate
gene studies may affect CRC risk and clinical outcome.
IFNAR1 has recently been proposed as a novel candidate CRC
tumor suppressor gene [21]. IFNAR1 has also been reported to
play an important role in the development of early-onset CRC,
suggesting a role in genetic predisposition [23]. Polymorphisms in
IFNAR1 have also been reported to be associated with
susceptibility of multiple sclerosis, hepatocellular carcinoma and
outcome of hepatitis B virus infection [32,33]. In our study, the
minor allele of rs2856968 in the intron of IFNAR1 was associated
with an increased risk of CRC. This polymorphism captured three
promoter SNPs rs2843710, rs17875753 and rs17875752 with high
LD (D9 = 1, r2 = 1). Rs2843710 is located in the binding site of
protein polymerase (DNA directed), epsilon, catalytic subunit
(POLE), which has been reported to be associated with colorectal
carcinogenesis [26,34]. Combined with the previously reported
associations of IFNAR1 with early-onset CRC and effects of
IFNAR1 on apoptosis and p53 signaling pathway in CRC cells
[13,21,23], our data support the role of IFNAR1 in CRC
causation.
The IFNGR1 protein is a prerequisite to the initiation of IFNG
signaling [35]. Reduced expression of IFNGR1 has been reported
to be associated with clinicopathologic characteristics of esopha-
geal cancer [36] and prognosis of ovarian cancer [37]. Published
studies have reported that polymorphisms in IFNGR1 are
significantly associated with susceptibility of chronic hepatitis B
virus infection, early gastric carcinoma, and rectal cancer
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in the promoter of IFNGR1 to be associated with an increased risk
of CRC. Rs2234711 has also been reported to be associated with
the susceptibility of early gastric carcinoma, chronic hepatitis B
virus infection and cerebral malaria [38–40]. A previous study
indicated that rs2234711 may have functional effects on stimulat-
ing B cell lines, and C allele was associated with decreased
IFNGR1 gene activity, however, in a context-dependent manner
[41]. Rs2234711 is located near an activating protein (AP)-2/AP-4
consensus binding site [42] and overexpression of AP-2a has been
shown to reduce the expression of IFNGR1 and to inhibit IFNG
signaling [35]. Moreover, rs2234711 is located in the binding site
of POLB, which has been associated with CRC [43,44]. Together
with evidences above, our finding suggested that the functional
variant rs2234711 might have an effect on CRC causation
through regulating the expression or function of IFNGR1.
Our study suggested an association of IFNA SNPs with clinical
outcome of CRC. Based on our data, the SNP rs6475526 may be
associated with overall and event-free survival of CRC patients.
The associations remained statistically significant after adjustment
for known prognostic markers, suggesting that rs6475526 is an
independent prognostic marker. Rs6475526 (about 2.2 kb 59 of
IFNA14) is capturing two IFNA7 promoter SNPs rs7045980 and
rs7046208 with high LD (D9$0.97, r2$0.85). According to
SNPinfo Web Server, all these SNPs are located nearby several
transcription factor binding sites and may thus affect transcrip-
tional activity. Previous studies have reported that IFNA-
expressing tumor cells enhance generation and promote survival
of tumor-specific cytotoxic T lymphocytes [45] and that IFNA
improves the anti-proliferative effect of EGFR inhibitors in CRC
cell lines [27,28]. Our finding gives novel evidence of the role of
IFNA in CRC progression and survival.
Compared to the previous study, which investigated the
association of tagSNPs in IFNG, IFNGR1, IFNGR2 and IRF1-
9 with the risk and survival of colon and rectal cancer [16], our
study focused on potentially functional SNPs and covered in
addition to the IRFs, IFNG and its receptors also other IFNs and
their receptors. Six genes, IFNG, IFNGR1, IFNGR2, IRF3,
IRF5 and IRF7, were common in these two studies. In contrast to
the previous study, which reported many associations both with
colon and rectal cancer risk and survival, we observed only two
associations with CRC risk and one association with overall and
event-free survival. The only gene showing association in both
studies was IFNGR1, however, the SNP rs2234711 which was
associated with CRC risk in our study, was not covered by any
tagSNP in the previous study. For the risk analysis, both studies
were large [Slattery et. al. case/control, 1555/1956 (colon cancer),
754/959 (rectal cancer); we 1327/758 (CRC)]. There may be
small differences in the origin of the study participants, with our
study coming from a genetically quite uniform Czech population
[22], while the recruitment area of the study by Slattery et. al. was
Northern California and Utah, including also some 10–20% of
Hispanic, Black and Asian participants. For the survival analysis,
the studies had comparable follow-up time, but while Slattery et.
al. had follow-up for all patients, we had it only for 483 patients,
which decreased our power to detect small associations. However,
this ensured that only newly diagnosed CRC cases (within one
year of diagnosis before enrollment for this study) were included in
our study, excluding a survival bias. For this subgroup, nearly
complete clinical data were available, allowing evaluation of the
SNPs as independent prognostic markers.
GWASs mainly describe only the most robust associations,
which may be the reason that they have not reported any
associations between CRC and interferon pathway genes. The
tagSNP approach, used in the GWAS, is thought as a method with
maximum SNP prediction accuracy, however, it does not cover all
SNPs in the regulatory regions. A total of 74 SNPs in the
regulatory and coding regions of the genes were covered by our
study. However, due to sample size restrictions, we concentrated
on SNPs with MAF $10% in Europeans and on SNPs located in
the basic regulatory regions. It is possible that SNPs with a lower
MAF or SNPs in still unknown regulatory regions of the studied
genes, such as the enhancer and the silencer regions, might also
modulate CRC susceptibility or survival.
In summary, our results, together with the previous study by
Slattery et. al. suggest that genetic variation in the IFN signaling
pathway genes plays a role in the etiology and survival of CRC.
The strongest findings of our study included the associations of
SNPs in IFNAR1 and IFNGR1 with susceptibility to CRC, and of
SNPs in IFNA7/IFNA14 with the survival of CRC patients.
Validation of our findings and investigation of novel genetic
variants in large, independent populations are encouraged.
Supporting Information
Figure S1 Haploview linkage disequilibrium (LD) pat-
tern of the interferon alpha region on chromosome
9p21.3 showing pairwise LD values r2 between the SNPs.
Only SNPs with the minor allele frequency.10% in the Utah
residents with Northern and Western European ancestry (CEU)
from the CEPH collection in the 1000 genomes project are shown.
Intensity of the gray color from white (r2 = 0) to black (r2 = 1)
indicates the extent of LD. The two IFNA7 promoter SNPs
rs7045980 and rs7046208 captured by rs6475526 (2.2 kb of
IFNA14) are surrounded by a red line.
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Table S1 Association of all evaluated SNPs with colo-
rectal cancer susceptibility in the whole study popula-
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survival and known prognostic factors.
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Table S3 Association of all evaluated SNPs with colo-
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free survival among patients without distant metastasis
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Table S4 Stratified analysis of rs6475526, rs7047687
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Figure 1. Kaplan-Meier analysis of survival according to genotypes of SNPs rs6475526, located 59 to IFNA14, and capturing two
IFN7 promoter SNPs and rs7047687 located in IFNA21 promoter. (A) Overall survival among all colorectal cancer patients (rs6475526,
n = 465). (B) Event-free survival among patients without distant metastasis at diagnosis (rs6477526, n = 310). (C) Overall survival among all colorectal
cancer patients (rs7047687, n = 464).
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